Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery 4Q/FY24 Financial Results February 26, 2025
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Digital Chemistry Laboratory Leverages Physics + AI
Digital Chemistry Laboratory Leverages Physics + AI Physics + AI Physics-based Training Set for AI/ML Artificial Intelligence / Methods Generated Using Physics Machine Learning ✓ No training set required ✓ Fast ✓ Effective at interpolation ✓ Can extrapolate into novel ✓ Accurate ✓ Fast chemical spac
Slide 4: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING • Life Sciences COLLABORATIONS • Materials Design • Drug Design PROPRIETARY PIPELINE ~1,752 customers worldwide1 • Materials Design 19 drug discovery collaborators2 • Drug Discovery & Development 8+ act
Slide 5: Highlights
Highlights 4Q24 Financial Results FY24 Financial Results 2025 Guidance Highlights • $88.3M total revenue • $208M total revenue • 10% - 15% software growth • $79.7M software revenue • $180M software revenue • $45M - $50M drug discovery • $8.7M drug discovery revenue • $27.2M drug discovery revenue re
Slide 6: Advancing the Platform in 2025
Advancing the Platform in 2025 Continuing to Integrate Physics & AI/ML Target Hit Lead Preclinical Validation Discovery Optimization Development High Resolution Protein Biologics Informatics Formulation & Crystal Structure Prediction Structure Prediction AI/ML Integration in Informatics Platform Vir
Slide 7: A Broad Portfolio of Advancing Collaboration Programs
A Broad Portfolio of Advancing Collaboration Programs(1)(2) Phase 1 Phase 2 Phase 3 FDA-Approved TIBSOVO4 Immuno-oncology Metabolic Diseases3 Psoriasis3 IDHIFA4 Obesity Inflammatory Bowel Disease5 Myelofibrosis Undisclosed Undisclosed Undisclosed Undisclosed Additional programs in discovery and prec
Slide 8: Proprietary Pipeline Approaching Key Clinical Milestones
Proprietary Pipeline Approaching Key Clinical Milestones DISCOVERY PRECLINICAL PHASE 1 SGR-1505 (MALT1) R/R B-cell Malignancies* SGR-2921 (CDC7) R/R AML/MDS* SGR-3515 (Wee1/Myt1) Solid Tumors SGR-4174 (SOS1) Solid Tumors EGFRC797S Solid Tumors PRMT5-MTA Solid Tumors NLRP3 Immunology LRRK2 Neurology
Slide 9: Clinical Programs with Breakthrough Potential
Clinical Programs with Breakthrough Potential SGR-1505 SGR-2921 SGR-3515 (MALT1) (CDC7) (Wee1/Myt1) • Generally well tolerated in • Potent and selective CDC7 • Clinically validated target healthy volunteers with no inhibition shows strong • Potential benefit in wide range dose-limiting tox or SAEs*
Slide 10: 4Q24 Financial Highlights vs. 4Q23
4Q24 Financial Highlights vs. 4Q23 Three Months Ended Dec. 31 Growth driven by hosted revenue 4Q 2023 4Q 2024 % Change as large customers transition from on-premise licenses Software revenue $68.7 $79.7 16% Drug discovery revenue $5.5 $8.7 58% New large, multi-year, on-premise agreements in Q424 mat
Slide 11: FY24 Financial Highlights vs. FY23
FY24 Financial Highlights vs. FY23 Twelve Months Ended Dec. 31 FY 2023 FY 2024 % Growth Software revenue $159.1 $180.4 13% Two thirds of software growth from hosted contracts Drug discovery revenue $57.5 $27.1 (53%) Total revenue $216.7 $207.5 (4.2%) Reduction in drug discovery revenue due to non-re
Slide 12: Software Quarterly Revenue Trend
Four-Quarter Trailing Average Software Quarterly Revenue Trend 50 45.1 42.3 39.8 40.1 41.6 40 33.9 33.7 33.5 34.6 30.0 31.5 31.6 30 28.3 $ Millions 23.8 24.6 24.9 23.1 21.3 19.6 20 18.0 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2020 2020 2020 2021 2021 2021 2021 2022 2022
Slide 13: Hosted Contracts Are a Growing Share of Total Software Revenue
Hosted Contracts Are a Growing Share of Total Software Revenue Hosted Contracts as % of Software Revenue (Trailing Hosted Contract Revenue 4-Quarter Average, %) Hosted Software Share of Software Revenue ($M) Revenue (%) Growth in Hosted Revenue vs. Growth in Hosted Contracts Growth in Total Software
Slide 14: Full Year 2024 Key Performance Indicators (KPIs)
Full Year 2024 Key Performance Indicators (KPIs) Software KPI 2023 2024 Total annual contract value (ACV) $154.2M $190.8M ACV of Top 10 Customers $51.0M $73.1M Number of customers with ACV ≥$5M 4 8 Number of customers with ACV ≥$1M 27 31 Number of customers with ACV ≥$500k 54 61 Number of customers
Slide 15: Continued Opportunity for Growth and Adoption within Large Biopharma
Continued Opportunity for Growth and Adoption within Large Biopharma* 0.15% 2024 Schrödinger ACV as % of 2023 R&D spend 0.10% 0.05% 0.00% $1 $5 Schrödinger 2024 ACV ($M) * Each dot represents the top 30 publicly-traded companies by total R&D expenditure for FY 2023. The X-axis represents each compan
Slide 16: 2025 Financial Guidance
2025 Financial Guidance (As of February 26, 2025) 2024 Actual 2025 Guidance Software revenue $180.4 + 10% – 15% Drug discovery revenue $27.2 $45 – $50 Software gross margin 80% 74% – 75% Operating expense growth 7.3% Less than 5% Cash used in operating activities $157.4 Lower than 2024 (in millions)
Slide 17: Strategic Priorities
Strategic Priorities • Increase customer adoption of computational technology • Deliver planned major enhancements to the platform • Present initial clinical data from the Phase 1 study of SGR-1505 in 2Q 2025 • Present initial clinical data from the Phase 1 study of SGR-2921 in 2H 2025 • Present ini
Slide 18: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery February 2025
Slide 19: Appendix
Appendix Annual Contract Value (ACV). With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period. For contracts with a duration of more than one